CHICAGO (EGMN) - Hypothyroidism is a frequent complication of many of the oral tyrosine kinase inhibitors being developed to treat malignancies, according to endocrinologist Jerome M. Hershman.This is a particularly common problem with sunitinib (Sutent), a multitarget vascular endothelial growth factor receptor tyrosine kinase inhibitor (TKI) marketed for the treatment of gastrointestinal stromal tumor and hepatocellular carcinoma; the drug also is in clinical trials for advanced thyroid cancer...